Dimolegin (dioxaban)
/ PharmaDiall
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
November 27, 2025
An Investigational Study on the Role of ADME Agents' Genetic Variation on DD217 Pharmacokinetics and Safety Profile.
(PubMed, Pharmaceuticals (Basel))
- "These observations are consistent with in silico predictions of metabolic and transporter pathways. Despite limitations in sample size and event frequency, the study highlights the feasibility and importance of early pharmacogenetic evaluation during the drug development cycle of novel DOACs."
Journal • PK/PD data • Cardiovascular • Hematological Disorders • Orthopedics • Pain • Thrombosis • ABCB1 • CYP2C19 • CYP2C9 • CYP3A4 • CYP3A5
August 18, 2025
Dimolegin® (60 mg) Given Once Daily in Patients Undergoing Total Hip or Knee Replacement Compared to Enoxaparin
(clinicaltrials.gov)
- P3 | N=215 | Completed | Sponsor: Avexima Diol LLC
New P3 trial • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Venous Thromboembolism
August 22, 2025
Dimolegin® (60 mg) for Patients With Moderate COVID-19: A Non-Interventional Study
(clinicaltrials.gov)
- P=N/A | N=184 | Completed | Sponsor: Avexima Diol LLC
New trial • Infectious Disease • Novel Coronavirus Disease
May 10, 2022
Investigation of the tight binding mechanism of a new anticoagulant DD217 to factor Xa by means of molecular docking and molecular dynamics.
(PubMed, J Biomol Struct Dyn)
- "The conducted analysis confirms the significant contributions to the MM/GBSA estimated binding free energy of the S4 pocket residues as well the crucial role of establishing the hydrogen bonds between the ligand and the backbone amides of Gly216 and Gly218 of the target. The simulation results support the hypothesis of the tight binding mechanism of DD217 to fXa.Communicated by Ramaswamy H. Sarma."
Journal
May 02, 2022
A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement
(clinicaltrials.gov)
- P2 | N=240 | Active, not recruiting | Sponsor: PharmaDiall Ltd. | Trial completion date: Jan 2022 ➔ Dec 2022
Trial completion date • Cardiovascular • Musculoskeletal Diseases • Orthopedics • Venous Thromboembolism
1 to 5
Of
5
Go to page
1